Participant Flow Module
The Participant Flow Module provides information about the flow of participants through each stage of the clinical trial. This includes pre-assignment details, recruitment information, and the types of units analyzed, helping researchers understand how participants move through the study.
Participant Flow Module path is as follows:
Study -> Results Section -> Participant Flow Module
Participant Flow Module
Ignite Creation Date:
2025-12-25 @ 3:38 AM
Ignite Modification Date:
2025-12-26 @ 2:22 AM
NCT ID:
NCT03725202
Pre Assignment Details:
Those assigned to upadacitinib who achieved sustained remission for at least 24 consecutive weeks prior to Week 52 visit (at the end of Period 1) were re-randomized in a 2:1 ratio to either stay on upadacitinib or switch to placebo in Period 2. Those on placebo who achieved sustained remission for at least 24 weeks prior to Week 52 visit continued on placebo in Period 2.
Recruitment Details:
This trial was conducted at 100 sites in 23 countries. Participants were randomized via in a 2:1:1 ratio to receive either upadacitinib 15 mg or 7.5 mg once daily in combination with a predefined 26-week CS taper regimen, or placebo with a predefined 52-week CS taper regimen
Study:
NCT03725202
Study Brief:
Results Section:
NCT03725202